XML 52 R35.htm IDEA: XBRL DOCUMENT
v3.23.3

License and Collaborations - Additional Information (Details) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2017 | Dec. 31, 2022
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Total revenues | $ 32,000,000 | $ 33,000,000 | $ 86,000,000 | $ 78,000,000 |  |
Other noncurrent liabilities | 145,000,000 |  | 145,000,000 |  |  | $ 140,000,000
Other noncurrent assets ($6 and $2 from a related party) | 108,000,000 |  | 108,000,000 |  |  | 114,000,000
AstraZeneca Agreement |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Development cost recorded within research and development expenses | 1,000,000 | 1,000,000 | 6,000,000 | 3,000,000 |  |
Other noncurrent liabilities | 11,000,000 |  | 11,000,000 |  |  | 5,000,000
Gilead Collaboration Agreement |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Total revenues |  |  | 1,000,000 |  |  |
Other noncurrent assets ($6 and $2 from a related party) | 6,000,000 |  | 6,000,000 |  |  | $ 2,000,000
Taiho Pharmaceutical Co., Ltd | Taiho Agreement |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Option period |  |  |  |  | 5 years |
Non refundable and non creditable cash payments |  |  |  |  | $ 35,000,000 |
Payment for option exercise | $ 28,000,000 |  |  |  |  |
Royalties payable term | 10 years |  |  |  |  |
Total revenues | $ 4,000,000 | 2,000,000 | 4,000,000 | 5,000,000 |  |
Reimbursement of research and development expense | 2,000,000 |  | 4,000,000 |  |  |
Taiho Pharmaceutical Co., Ltd | Taiho Agreement | Minimum |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Payment for option exercise |  |  |  |  | 3,000,000 |
Taiho Pharmaceutical Co., Ltd | Taiho Agreement | Maximum |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Payment for option exercise |  |  |  |  | 15,000,000 |
Additional clinical and regulatory milestone payments receivable |  |  |  |  | 130,000,000 |
Contingent milestone payments receivable |  |  |  |  | $ 145,000,000 |
WuXi Biologics License Agreement | anti-CD39 | Research and Development |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Development milestone expense | $ 0 | $ 0 | 1,000,000 | $ 2,000,000 |  |
WuXi Biologics License Agreement | Maximum | anti-PD-1 |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Clinical, regulatory and commercialization milestone payments |  |  | 375,000,000 |  |  |
WuXi Biologics License Agreement | Maximum | anti-CD39 |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Additional clinical, regulatory and commercialization milestone payments |  |  | 14,000,000 |  |  |
Abmuno License Agreement |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Additional clinical, regulatory and commercialization milestone payments |  |  | $ 88,000,000 |  |  |

X
- Definition Additional clinical and milestone payments received under license agreement. + References No definition available. + Details
Name: | rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional clinical regulatory and commercialization milestone payments. + References No definition available. + Details
Name: | rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Clinical regulatory and commercialization milestone payments. + References No definition available. + Details
Name: | rcus_ClinicalRegulatoryAndCommercializationMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent milestone payments receivable. + References No definition available. + Details
Name: | rcus_ContingentMilestonePaymentsReceivable
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License and collaboration agreements. + References No definition available. + Details
Name: | rcus_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone expense. + References No definition available. + Details
Name: | rcus_MilestoneExpense
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable and non creditable cash payments. + References No definition available. + Details
Name: | rcus_NonRefundableAndNonCreditableCashPayments
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option period. + References No definition available. + Details
Name: | rcus_OptionPeriod
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment for option exercise. + References No definition available. + Details
Name: | rcus_PaymentForOptionExercise
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursement of research and development expense + References No definition available. + Details
Name: | rcus_ReimbursementOfResearchAndDevelopmentExpense
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalties Payable Term + References No definition available. + Details
Name: | rcus_RoyaltiesPayableTerm
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of noncurrent assets classified as other. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherAssetsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rcus_AntiCDThirtyNineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rcus_AntiPDOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |